

**RE: HRSA Review of 340B Program Audit-
AtlantiCare Regional Medical Center (ARMC; 340B ID DSH310064)**

Dear Manufacturers:

I am writing on behalf of AtlantiCare Regional Medical Center (340B ID # DSH310064), (“AtlantiCare”) to inform manufacturers that AtlantiCare recently underwent an audit by the Health Resources and Services Administration (“HRSA”) of AtlantiCare’s compliance with 340B Drug Pricing Program (“340B Program”) requirements.

As background, AtlantiCare qualified for the 340B Program as an acute-care hospital located in Atlantic County, New Jersey, and has participated in the 340B Program since July 1, 2012.

Through the audit process, AtlantiCare was found to have non-compliance within their 340B Program and responsibility for repayment as a result of the following finding:

ARMC dispensed 340B drugs to ineligible individuals, as prohibited by section 340B(a)(5)(B) of the PHSA.

AtlantiCare has identified all affected manufacturers and has contact each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. IF manufacturers have not received notification from AtlantiCare and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Hak Kim, VP Financial Planning, (609) 569-7031, AtlantiCare, 2500 English Creek Avenue, Bldg 500, Egg Harbor Township, NJ 08234.

Respectfully submitted,

Hak Kim
VP Financial Planning